Compare XNCR & SSYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XNCR | SSYS |
|---|---|---|
| Founded | 1997 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer peripheral equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 937.1M | 783.1M |
| IPO Year | 2013 | 2012 |
| Metric | XNCR | SSYS |
|---|---|---|
| Price | $15.05 | $8.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | ★ $22.33 | $12.33 |
| AVG Volume (30 Days) | 770.4K | ★ 1.2M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $125,576,000.00 | N/A |
| Revenue This Year | N/A | $4.48 |
| Revenue Next Year | $4.80 | $3.23 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 13.65 | N/A |
| 52 Week Low | $6.92 | $7.34 |
| 52 Week High | $18.69 | $12.78 |
| Indicator | XNCR | SSYS |
|---|---|---|
| Relative Strength Index (RSI) | 73.30 | 38.03 |
| Support Level | $10.94 | $8.15 |
| Resistance Level | $15.59 | $8.24 |
| Average True Range (ATR) | 0.75 | 0.39 |
| MACD | 0.32 | -0.11 |
| Stochastic Oscillator | 80.78 | 2.05 |
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
Stratasys Ltd offers polymer-based 3D printing solutions for designers, engineers, manufacturers, dental and medical professionals, and others. Its 3D printing systems utilize the firm's patented extrusion-based FDM, inkjet-based PolyJet, powder-bed-based SAF, photopolymer-based P3, and Neo stereolithography technologies to enable the production of prototypes, tools, and manufactured goods directly from 3D CAD files or other 3D content. The company's solutions portfolio comprises 3D printing systems, consumables, software, paid parts, and professional services, allowing end-users to effectively print 3D models, tools, and parts. Geographically, it generates maximum revenue from the United States, followed by Europe, Middle East and Africa, Asia-Pacific, and other regions.